# A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

> **NCT05567367** · PHASE1 · COMPLETED · sponsor: **Respira Therapeutics, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **COMBINATION_PRODUCT:** Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- **DRUG:** Vardenafil Oral Tablet

## Key facts

- **NCT ID:** NCT05567367
- **Lead sponsor:** Respira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-31
- **Primary completion:** 2019-12-04
- **Final completion:** 2019-12-04
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05567367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05567367, "A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05567367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*